Mirtazapina Flas Ratiopharm (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This combined effect enhances serotonergic and noradrenergic signaling while reducing histamine‑mediated sedation, producing antidepressant and anxiolytic benefits.

The appropriate dose of Mirtazapina Flas Ratiopharm is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in strong sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Mirtazapina Flas Ratiopharm is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, seizures, severe hypotension, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, especially during the initial treatment period. Prompt medical attention is required if any of these events occur.

Mirtazapina Flas Ratiopharm should be avoided in patients with known hypersensitivity to mirtazapine or any excipients, those currently taking monoamine oxidase inhibitors, and individuals with uncontrolled severe cardiovascular disease without careful medical supervision.